Table 1.
Comparison of Baseline Characteristics of the Study Population
| β‐Adrenergic–Antagonist Therapy, n = 16 | No β Adrenergic–Antagonist Therapy, n = 48 | |
|---|---|---|
| Demographics | ||
| Age, mean (± SD), ya | 74.1 (±9.0) | 65.9 (±12.1) |
| Gender, n (%) | ||
| M | 2 (12.5) | 4 (8.33) |
| F | 14 (87.5) | 44 (91.66) |
| Race, n (%) | ||
| Caucasian | 11 (68.75) | 47 (97.91) |
| African American | 1 (6.25) | 0 |
| Unknown | 4 (25) | 1 (2.1) |
| Medications | ||
| β‐Blocker (%) | Metoprolol tartrate (37.5), metoprolol succinate (50), atenolol (12.5) | None |
| ACEI/ARB, n (%) | 11 (68.75) | 14 (21.53) |
| Statin, n (%) | 9 (56.25) | 20 (41.66) |
| Cardiovascular risk factors, n (%) | ||
| Hypertension | 14 (87.5) | 24 (50) |
| PAD | 2 (12.5) | 1 (2.08) |
| DM | 3 (18.5) | 11 (22.91) |
| Dyslipidemia | 7 (43.75) | 23 (47.91) |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; DM, diabetes mellitus; F, female; M, male; PAD, peripheral arterial disease.
a
P < 0.05.